家族性大腸腺腫症 - 市場の洞察、疫学、市場予測：2034年

今後数年間で、家族性大腸腺腫症市場は、この疾患に対する認識の高まりと、世界全体の医療支出の増加により変化するとみられます。

企業や研究機関は、家族性大腸腺腫症の研究開発に影響を与えうる課題を評価し、その機会を探るべく取り組んでいます。開発中の治療法は、病態を治療/改善するための新規アプローチに焦点を当てています。主要企業は家族性大腸腺腫症の治療法開発に関与しています。新たな治療法の登場は、家族性大腸腺腫症市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における家族性大腸腺腫症市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 家族性大腸腺腫症のエグゼクティブサマリー

第3章 家族性大腸腺腫症の競合情報分析

第4章 家族性大腸腺腫症：市場概要

第5章 家族性大腸腺腫症：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第6章 患者動向

第7章 家族性大腸腺腫症の疫学と患者人口

• 疫学の主な調査結果
• 前提と根拠：主要7ヶ国
• 疫学シナリオ：主要7ヶ国
• 米国
• 欧州5ヶ国
• 日本疫学

第8章 治療アルゴリズム、現在の治療、医療行為

第9章 アンメットニーズ

第10章 家族性大腸腺腫症治療の主要評価項目

第11章 上市済み製品

第12章 新たな治療法

第13章 家族性大腸腺腫症：主要7ヶ国市場分析

第14章 属性分析

第15章 主要7ヶ国：市場見通し

• 米国：市場規模
• 欧州5ヶ国：市場規模と展望
• ドイツ市場規模
• フランス市場規模
• イタリア市場規模
• スペイン市場規模
• 英国市場規模
• 日本市場規模

第16章 家族性大腸腺腫症のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Familial Adenomatous Polyposis Epidemiology (2020-2034)
• Table 2: 7MM Familial Adenomatous Polyposis Diagnosed and Treatable Cases (2020-2034)
• Table 3: Familial Adenomatous Polyposis Epidemiology in the United States (2020-2034)
• Table 4: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Familial Adenomatous Polyposis Epidemiology in Germany (2020-2034)
• Table 6: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Familial Adenomatous Polyposis Epidemiology in France (2020-2034)
• Table 8: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Familial Adenomatous Polyposis Epidemiology in Italy (2020-2034)
• Table 10: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Familial Adenomatous Polyposis Epidemiology in Spain (2020-2034)
• Table 12: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Familial Adenomatous Polyposis Epidemiology in the UK (2020-2034)
• Table 14: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Familial Adenomatous Polyposis Epidemiology in Japan (2020-2034)
• Table 16: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Familial Adenomatous Polyposis Epidemiology (2020-2034)
• Figure 2: 7MM Familial Adenomatous Polyposis Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Familial Adenomatous Polyposis Epidemiology in the United States (2020-2034)
• Figure 4: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Familial Adenomatous Polyposis Epidemiology in Germany (2020-2034)
• Figure 6: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Familial Adenomatous Polyposis Epidemiology in France (2020-2034)
• Figure 8: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Familial Adenomatous Polyposis Epidemiology in Italy (2020-2034)
• Figure 10: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Familial Adenomatous Polyposis Epidemiology in Spain (2020-2034)
• Figure 12: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Familial Adenomatous Polyposis Epidemiology in the UK (2020-2034)
• Figure 14: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Familial Adenomatous Polyposis Epidemiology in Japan (2020-2034)
• Figure 16: Familial Adenomatous Polyposis Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Familial Adenomatous Polyposis - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Familial Adenomatous Polyposis, historical and forecasted epidemiology as well as the Familial Adenomatous Polyposis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Familial Adenomatous Polyposis market report provides current treatment practices, emerging drugs, Familial Adenomatous Polyposis market share of the individual therapies, current and forecasted Familial Adenomatous Polyposis market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Familial Adenomatous Polyposis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Familial Adenomatous Polyposis Disease Understanding and Treatment Algorithm

The DelveInsight Familial Adenomatous Polyposis market report gives a thorough understanding of the Familial Adenomatous Polyposis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Familial Adenomatous Polyposis.

Treatment

It covers the details of conventional and current medical therapies available in the Familial Adenomatous Polyposis market for the treatment of the condition. It also provides Familial Adenomatous Polyposis treatment algorithms and guidelines in the United States, Europe, and Japan.

Familial Adenomatous Polyposis Epidemiology

The Familial Adenomatous Polyposis epidemiology division provide insights about historical and current Familial Adenomatous Polyposis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Familial Adenomatous Polyposis Epidemiology

The epidemiology segment also provides the Familial Adenomatous Polyposis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Familial Adenomatous Polyposis Drug Chapters

Drug chapter segment of the Familial Adenomatous Polyposis report encloses the detailed analysis of Familial Adenomatous Polyposis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Familial Adenomatous Polyposis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Familial Adenomatous Polyposis treatment.

Familial Adenomatous Polyposis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Familial Adenomatous Polyposis treatment.

Familial Adenomatous Polyposis Market Outlook

The Familial Adenomatous Polyposis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Familial Adenomatous Polyposis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Familial Adenomatous Polyposis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Familial Adenomatous Polyposis market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Familial Adenomatous Polyposis market in 7MM.

The United States Market Outlook

This section provides the total Familial Adenomatous Polyposis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Familial Adenomatous Polyposis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Familial Adenomatous Polyposis market size and market size by therapies in Japan is also mentioned.

Familial Adenomatous Polyposis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Familial Adenomatous Polyposis market or expected to get launched in the market during the study period 2020-2034. The analysis covers Familial Adenomatous Polyposis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Familial Adenomatous Polyposis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Familial Adenomatous Polyposis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Familial Adenomatous Polyposis emerging therapies.

Reimbursement Scenario in Familial Adenomatous Polyposis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Familial Adenomatous Polyposis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Familial Adenomatous Polyposis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Familial Adenomatous Polyposis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Familial Adenomatous Polyposis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Familial Adenomatous Polyposis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Familial Adenomatous Polyposis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Familial Adenomatous Polyposis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Familial Adenomatous Polyposis market

Report Highlights:

• In the coming years, Familial Adenomatous Polyposis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Familial Adenomatous Polyposis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Familial Adenomatous Polyposis. Launch of emerging therapies will significantly impact the Familial Adenomatous Polyposis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Familial Adenomatous Polyposis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Familial Adenomatous Polyposis Report Insights

• Patient Population
• Therapeutic Approaches
• Familial Adenomatous Polyposis Pipeline Analysis
• Familial Adenomatous Polyposis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Familial Adenomatous Polyposis Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Familial Adenomatous Polyposis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Familial Adenomatous Polyposis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Familial Adenomatous Polyposis market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Familial Adenomatous Polyposis total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Familial Adenomatous Polyposis market size during the forecast period (2024-2034)?
• At what CAGR, the Familial Adenomatous Polyposis market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Familial Adenomatous Polyposis market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Familial Adenomatous Polyposis market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Familial Adenomatous Polyposis?
• What is the historical Familial Adenomatous Polyposis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Familial Adenomatous Polyposis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Adenomatous Polyposis?
• Out of all 7MM countries, which country would have the highest prevalent population of Familial Adenomatous Polyposis during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Familial Adenomatous Polyposis treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Familial Adenomatous Polyposis in the USA, Europe, and Japan?
• What are the Familial Adenomatous Polyposis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Familial Adenomatous Polyposis?
• How many therapies are developed by each company for Familial Adenomatous Polyposis treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Familial Adenomatous Polyposis treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Familial Adenomatous Polyposis therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Familial Adenomatous Polyposis and their status?
• What are the key designations that have been granted for the emerging therapies for Familial Adenomatous Polyposis?
• What are the global historical and forecasted market of Familial Adenomatous Polyposis?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Familial Adenomatous Polyposis market
• To understand the future market competition in the Familial Adenomatous Polyposis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Familial Adenomatous Polyposis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Familial Adenomatous Polyposis market
• To understand the future market competition in the Familial Adenomatous Polyposis market

Table of Contents

1. Key Insights

2. Executive Summary of Familial Adenomatous Polyposis

3. Competitive Intelligence Analysis for Familial Adenomatous Polyposis

4. Familial Adenomatous Polyposis: Market Overview at a Glance

• 4.1. Familial Adenomatous Polyposis Total Market Share (%) Distribution in 2020
• 4.2. Familial Adenomatous Polyposis Total Market Share (%) Distribution in 2034

5. Familial Adenomatous Polyposis: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Familial Adenomatous Polyposis Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Familial Adenomatous Polyposis Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Familial Adenomatous Polyposis Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Familial Adenomatous Polyposis Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Familial Adenomatous Polyposis Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Familial Adenomatous Polyposis Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Familial Adenomatous Polyposis Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Familial Adenomatous Polyposis Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Familial Adenomatous Polyposis Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Familial Adenomatous Polyposis Treatment and Management
• 8.2. Familial Adenomatous Polyposis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Familial Adenomatous Polyposis Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Familial Adenomatous Polyposis: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Familial Adenomatous Polyposis Market Size in 7MM
• 13.3. Familial Adenomatous Polyposis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Familial Adenomatous Polyposis Total Market Size in the United States
  • 15.1.2. Familial Adenomatous Polyposis Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Familial Adenomatous Polyposis Total Market Size in Germany
  • 15.3.2. Familial Adenomatous Polyposis Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Familial Adenomatous Polyposis Total Market Size in France
  • 15.4.2. Familial Adenomatous Polyposis Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Familial Adenomatous Polyposis Total Market Size in Italy
  • 15.5.2. Familial Adenomatous Polyposis Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Familial Adenomatous Polyposis Total Market Size in Spain
  • 15.6.2. Familial Adenomatous Polyposis Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Familial Adenomatous Polyposis Total Market Size in the United Kingdom
  • 15.7.2. Familial Adenomatous Polyposis Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Familial Adenomatous Polyposis Total Market Size in Japan
  • 15.8.3. Familial Adenomatous Polyposis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Familial Adenomatous Polyposis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.